Vertex Pharmaceuticals


Stock Issuer and Owners

Home | Sign Up | Log In
List of Funds
Boston Firms
Boston Hedge Funds
Cornell Alumni Firms
CalPERS Portfolio
NYSCRF Portfolio
Latest Filings
User Guide
Regulatory AUM vs AUM
LP Portfolios
Related Firms
Build a Portfolio
Comprehensive Search
Vertex Pharmaceuticals
CIK #0000875320
SectorLife Sciences
IndustryPharmaceutical Preparations
Address130 Waverly Street
Cambridge, MA 02139-4242
Source [EDGAR]
Market Cap, 13F ($BB)

We invest in scientific innovation to create transformative medicines for people with serious diseases with a focus on specialty markets.

Our goal is to develop treatment regimens that will provide benefits to all patients with cystic fibrosis, or CF, and will enhance the benefits that currently are being provided to patients taking our medicines. Our marketed medicines are TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor) and KALYDECO (ivacaftor). We obtained approval from the U.S. Food and Drug Administration, or the FDA, for TRIKAFTA, our triple combination regimen, in October 2019. This approval increased the number of patients eligible for our medicines in the U.S. by approximately 6,000 and provided an additional treatment option for many patients who are also eligible for one of our previously approved products. We have submitted a Marketing Authorization Application, or MAA, to the European Medicines Agency, or EMA, for this triple combination regimen. The FDA approval and the MAA filing were based on positive data from Phase 3 clinical trials evaluating the triple combination regimen in patients 12 years of age or older (i) who have a copy of the F508del mutation in their cystic fibrosis transmembrane conductance regulator, or CFTR, gene and a second mutation that results in minimal CFTR function, whom we refer to as F508del/Min patients, and (ii) who have two copies of the F508del mutation, whom we refer to as F508del homozygous patients. Our four medicines are collectively approved to treat approximately 60% of the 75,000 CF patients in North America, Europe and Australia. We are focused on obtaining approval for the triple combination in ex-U.S. markets for patients 12 years of age and older and evaluating our triple combination in younger patients, with the goal of having treatments for up to 90% of patients with CF. We are also pursuing other therapeutic approaches to address the remaining 10% of CF patients.

Our goal is to identify and develop new medicines by combining transformative advances in the understanding of human disease and in the science of therapeutics to advance human health.

CIK Filing 2011 - 2021
[0000875320] 10-K
[0000875320] 10-Q
[0000875320] 3
[0000875320] 4
[0000875320] 5
[0000875320] 8-K
[0000875320] SC 13D
[0000875320] SC 13G
Form 13D/13G Filer Form 13D/13G Subject Filed % Owned
Vertex Pharmaceuticals Inc / Ma Kymera Therapeutics Inc [2020-09-03] 7.1
Vertex Pharmaceuticals Inc / Ma Crispr Therapeutics AG [2019-11-26] 0.1
Vertex Pharmaceuticals Inc / Ma Crispr Therapeutics AG [2018-12-21] 10.1
Vanguard Specialized Funds Vertex Pharmaceuticals Inc / Ma [2017-02-13] 5.33
Vertex Pharmaceuticals Inc / Ma Crispr Therapeutics AG [2017-02-13] 8.0
JPMorgan Chase & Co Vertex Pharmaceuticals Inc / Ma [2016-02-01] 5.1
FMR LLC Vertex Pharmaceuticals Inc / Ma [2015-02-13] 0.0
Price T Rowe Associates Inc /MD/ Vertex Pharmaceuticals Inc / Ma [2015-02-12] 5.5
Wellington Management Co LLP Vertex Pharmaceuticals Inc / Ma [2014-02-14] 7.08
Vanguard Group Inc Vertex Pharmaceuticals Inc / Ma [2014-02-12] 6.73
Jennison Associates LLC Vertex Pharmaceuticals Inc / Ma [2012-02-14] 5.0
Prudential Financial Inc Vertex Pharmaceuticals Inc / Ma [2012-02-14] 5.2
Form 3/4/5 Filer 2011-2021
Arbuckle Stuart A
Sachdev Amit
Parini Michael
Altshuler David
Sachs Bruce I
McKenzie Diana
Bhatia Sangeeta N
McGlynn Margaret G
Kewalramani Reshma
Silva Paul M
Wagner Charles F Jr
Leiden Jeffrey M
Young William D
Lee Yuchun
Kearney Terrence C
Garber Alan M
Carney Lloyd
Bozic Carmen
Tatsis Ourania
Ullian Elaine
Crispr Therapeutics AG
Vertex Pharmaceuticals Europe Ltd
Graney Thomas
Smith Ian F
Chodakewitz Jeffrey
Boger Joshua S
Riley Wayne Joseph
Connolly Thomas
Horton Kenneth L
Pace Megan E
Mueller Peter
Stamoulis Christiana
Kelly Lisa
Emmens Matthew
Wysenski Nancy
Winger Dennis L
Howton David T
MM Shares Owned of 255.5 MM Total
Firm Period DFND Voting Shares
BlackRock Inc. [2020-09-30] SOLE 22.6 25.2
Price T Rowe Associates Inc /MD/ [2020-09-30] SOLE 7.1 20.4
FMR LLC [2020-09-30] DFND 3.1 20.1
Vanguard Group Inc [2020-09-30] SOLE 0.0 19.5
State Street Corp [2020-09-30] DFND 9.9 11.4
Capital World Investors [2020-09-30] DFND 11.4 11.4
AllianceBernstein LP [2020-09-30] DFND 6.1 6.6
Wellington Management Co LLP [2020-09-30] DFND 0.0 6.2
Capital Research & Management Co - Division 3 [2020-09-30] DFND 5.5 5.5
Renaissance Technologies LLC [2020-09-30] SOLE 5.1 5.2
Clearbridge Investments LLC [2020-09-30] SOLE 4.4 4.5
Geode Capital Management LLC [2020-09-30] DFND 3.9 3.9
Jennison Associates LLC [2020-09-30] DFND 3.5 3.6
Nuveen Asset Management LLC [2020-09-30] DFND 3.5 3.5
Northern Trust Corp [2020-09-30] DFND 0.8 3.0
Bank of New York Mellon Corp [2020-09-30] DFND 2.1 2.6
JPMorgan Chase & Co [2020-09-30] DFND 1.9 2.2
California Public Employees Retirement System [2020-09-30] SOLE 2.2 2.2
Goldman Sachs Group Inc [2020-09-30] DFND 2.0 2.1
DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt [2020-09-30] DFND 1.6 2.1
Harding Loevner LP [2020-09-30] SOLE 0.0 2.0
Henderson Group PLC [2020-09-30] DFND 0.0 1.9
Waddell & Reed Financial Inc [2020-09-30] DFND 1.7 1.7
Legal & General Group Plc [2020-09-30] DFND 1.2 1.7
Massachusetts Financial Services Co /MA/ [2020-09-30] SOLE 1.6 1.7
Bank of America Corp /DE/ [2020-09-30] DFND 0.2 1.5
Wells Fargo & Co/Mn [2020-09-30] DFND 1.2 1.5
Swiss National Bank [2020-09-30] SOLE 1.4 1.4
GQG Partners LLC [2020-09-30] SOLE 1.2 1.4
Sumitomo Mitsui Trust Holdings, Inc. [2020-09-30] DFND 1.3 1.3
Prev | Page 1 | Next
Terms | Privacy | Guide